NA Veterinary Pain Management Market - Industry Trends and Forecast to 2034

Description

List of Tables

North America veterinary pain management market is expected to reach USD 1,256,306.51 thousand by 2030 from USD 728,148.69 thousand in 2022 growing at a CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation

North America Veterinary Pain Management Market, By Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion Animal and Production Animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030.

Overview of North America Veterinary Pain Management Market Dynamics

Driver
Rising incidences of pet diseases
Restraint
High costs of pet care
Opportunity
Technological advancements for pain management

Market Players

Some of the major market players operating in the North America veterinary pain management market are:

Dechra Pharmaceuticals PLC
Virbac
Norbrook
Durvet Animal Health Products
Bimeda, Inc.
Inovet ( A subsidiary of Orion Group)
Chanelle Pharma
Vetoquinol
Elanco
Merck & Co., Inc.
Zoetis Services LLC
Ceva Animal Health, LLC

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET 17
1.4 CURRENCY AND PRICING 19
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 20

2 MARKET SEGMENTATION 23

2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 MULTIVARIATE MODELLING 30
2.7 MARKET END USER COVERAGE GRID 30
2.8 PRODUCT LIFELINE CURVE 31
2.9 DBMR MARKET POSITION GRID 32
2.10 VENDOR SHARE ANALYSIS 33
2.11 SECONDARY SOURCES 34
2.12 ASSUMPTIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 38

4.1 PESTEL ANALYSIS 39
4.2 PORTER'S FIVE FORCES 40
4.3 BRAND REVENUE ANALYSIS 41

5 MARKET OVERVIEW 42

5.1 DRIVERS 44
- 5.1.1 INCREASING PET OWNERSHIP 44
- 5.1.2 ADVANCEMENTS IN VETERINARY MEDICINE 44
- 5.1.3 GROWING INCIDENCES OF PET DISEASES 45
- 5.1.4 INCREASED GOVERNMENT PROJECTS TO ENHANCE ANIMAL CARE 45
5.2 RESTRAINTS 46
- 5.2.1 INCREASING PET CARE COSTS 46
- 5.2.2 STRICT REGULATORY GUIDELINES 46
5.3 OPPORTUNITIES 47
- 5.3.1 RISING R&D ACTIVITIES AND PRODUCT APPROVAL FOR VETERINARY PAIN MANAGEMENT 47
- 5.3.2 RISING POPULARITY OF NON- CONVENTIONAL TREATMENT APPROACHES 48
- 5.3.3 TECHNOLOGICAL ADVANCEMENTS 48
5.4 CHALLENGES 49
- 5.4.1 LIMITED AVAILABILITY OF VETERINARIANS 49
- 5.4.2 RESISTANCE TO MEDICATIONS 49

6 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE 50

6.1 OVERVIEW 51
6.2 ANALGESICS 52
- 6.2.1 ANTI- INFLAMMATORY (NSAIDS) 52
  - 6.2.1.1 CARPROFEN 53
  - 6.2.1.2 MELOXICAM 53
  - 6.2.1.3 PHENYLBUTAZONE 53
  - 6.2.1.4 ACETAMINOPHEN 53
  - 6.2.1.5 FIROCOXIB 53
  - 6.2.1.6 DERACOXIB 53
  - 6.2.1.7 OTHERS 54
- 6.2.2 OPIOIDS 54
  - 6.2.2.1 MU AGONISTS 54
    - 6.2.2.1.1 METHADONE 55
    - 6.2.2.1.2 MEPERIDINE 55
    - 6.2.2.1.3 MORPHINE 55
    - 6.2.2.1.4 OXYMORPHONE 55
    - 6.2.2.1.5 OTHERS 55
  - 6.2.2.2 PARTIAL MU AGONIST 55
    - 6.2.2.2.1 BUPRENORPHINE 55
    - 6.2.2.2.2 OTHERS 56
  - 6.2.2.3 KAPPA AGONIST MU ANTAGONIST 56
    - 6.2.2.3.1 BUTORPHANOL 56
    - 6.2.2.3.2 OTHERS 56
6.3 CORTICOSTEROIDS 57
- 6.3.1 DEXAMETHASONE 57
- 6.3.2 PREDNISOLONE 57
- 6.3.3 PREDNISONE 57
- 6.3.4 OTHERS 58
6.4 ALPHA 2 AGONISTS 58

7 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE 59

7.1 OVERVIEW 60
7.2 BRANDED 61
7.3 GENERIC 61

8 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE 62

8.1 OVERVIEW 63
8.2 PRESCRIPTION BASED 64
8.3 OTC 64

9 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE 65

9.1 OVERVIEW 66
9.2 COMPANION ANIMAL 67
- 9.2.1 CANINE 68
- 9.2.2 EQUINE 68
- 9.2.3 FELINE 68
- 9.2.4 OTHERS 68
9.3 PRODUCTION ANIMAL 68
- 9.3.1 CATTLE 69
- 9.3.2 SWINE 69
- 9.3.3 POULTRY 69
- 9.3.4 FISH 69
- 9.3.5 OTHERS 69

10 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE 70

10.1 OVERVIEW 71
10.2 CHRONIC PAIN 72
10.3 ACUTE PAIN 73
10.4 POST OPERATIVE PAIN 73
10.5 DENTAL PAIN 74

11 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE 75

11.1 OVERVIEW 76
11.2 SOLID 77
- 11.2.1 TABLET 77
- 11.2.2 POWDER 78
- 11.2.3 OTHERS 78
11.3 LIQUID 78
- 11.3.1 SOLUTION 78
- 11.3.2 SYRUP 79
- 11.3.3 SUSPENSION 79
- 11.3.4 OTHERS 79
11.4 SEMI SOLID 79
- 11.4.1 GEL 80
- 11.4.2 CREAM 80
- 11.4.3 OTHERS 80

12 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION 81

12.1 OVERVIEW 82
12.2 PARENTERAL 83
12.3 ORAL 84
12.4 TOPICAL 84

13 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 VETERINARY HOSPITALS 87
13.3 VETERINARY CLINICS 88
13.4 PET SHOPS 88
13.5 ANIMAL FARMS 89
13.6 ACADEMIC & RESEARCH INSTITUTES 89
13.7 OTHERS 90

14 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY GEOGRAPHY 91

14.1 NORTH AMERICA 92
- 14.1.1 U.S. 100
- 14.1.2 CANADA 107
- 14.1.3 MEXICO 115

15 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, COMPANY LANDSCAPE 122

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 122

16 SWOT ANALYSIS 123

17 COMPANY PROFILE 124

17.1 ZOETIS SERVICES LLC 124
- 17.1.1 COMPANY SNAPSHOT 124
- 17.1.2 COMPANY SHARE ANALYSIS 124
- 17.1.3 PRODUCT PORTFOLIO 125
- 17.1.4 RECENT DEVELOPMENTS 125
17.2 ELANCO 126
- 17.2.1 COMPANY SNAPSHOT 126
- 17.2.2 REVENUE ANALYSIS 126
- 17.2.3 COMPANY SHARE ANALYSIS 127
- 17.2.4 PRODUCT PORTFOLIO 127
- 17.2.5 RECENT DEVELOPMENT 127
17.3 MERCK & CO., INC. 128
- 17.3.1 COMPANY SNAPSHOT 128
- 17.3.2 REVENUE ANALYSIS 128
- 17.3.3 COMPANY SHARE ANALYSIS 129
- 17.3.4 PRODUCT PORTFOLIO 129
- 17.3.5 RECENT DEVELOPMENT 129
17.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 130
- 17.4.1 COMPANY SNAPSHOT 130
- 17.4.2 COMPANY SHARE ANALYSIS 130
- 17.4.3 PRODUCT PORTFOLIO 131
- 17.4.4 RECENT DEVELOPMENT 131
17.5 VETOQUINOL 132
- 17.5.1 COMPANY SNAPSHOT 132
- 17.5.2 REVENUE ANALYSIS 132
- 17.5.3 COMPANY SHARE ANALYSIS 133
- 17.5.4 PRODUCT PORTFOLIO 133
- 17.5.5 RECENT DEVELOPMENTS 133
17.6 BIMEDA, INC. 135
- 17.6.1 COMPANY SNAPSHOT 135
- 17.6.2 PRODUCT PORTFOLIO 135
- 17.6.3 RECENT DEVELOPMENT 135
17.7 CEVA ANIMAL HEALTH, LLC 136
- 17.7.1 COMPANY SNAPSHOT 136
- 17.7.2 PRODUCT PORTFOLIO 136
- 17.7.3 RECENT DEVELOPMENT 136
17.8 CHANELLE PHARMA 137
- 17.8.1 COMPANY SNAPSHOT 137
- 17.8.2 PRODUCT PORTFOLIO 137
- 17.8.3 RECENT DEVELOPMENT 137
17.9 DECHRA PHARMACEUTICALS PLC 138
- 17.9.1 COMPANY SNAPSHOT 138
- 17.9.2 REVENUE ANALYSIS 138
- 17.9.3 PRODUCT PORTFOLIO 139
- 17.9.4 RECENT DEVELOPMENTS 139
17.10 DURVET ANIMAL HEALTH PRODUCTS 140
- 17.10.1 COMPANY SNAPSHOT 140
- 17.10.2 PRODUCT PORTFOLIO 140
- 17.10.3 RECENT DEVELOPMENT 140
17.11 INOVET (A SUBSIDIARY OF ORION GROUP) 141
- 17.11.1 COMPANY SNAPSHOT 141
- 17.11.2 PRODUCT PORTFOLIO 141
- 17.11.3 RECENT DEVELOPMENTS 141
17.12 NORBROOK 143
- 17.12.1 COMPANY SNAPSHOT 143
- 17.12.2 PRODUCT PORTFOLIO 143
- 17.12.3 RECENT DEVELOPMENT 143
17.13 VIRBAC 144
- 17.13.1 COMPANY SNAPSHOT 144
- 17.13.2 REVENUE ANALYSIS 144
- 17.13.3 PRODUCT PORTFOLIO 145
- 17.13.4 RECENT DEVELOPMENT 145

18 QUESTIONNAIRE 146

19 RELATED REPORTS 150

LIST OF TABLES

TABLE 1 BRAND REVENUE ANALYSIS FOR VETERINARY PAIN MANAGEMENT MARKET 41
TABLE 2 NUMBER OF U.S. HOUSEHOLD-OWNED PET ANIMALS 44
TABLE 3 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 52
TABLE 4 NORTH AMERICA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 52
TABLE 5 NORTH AMERICA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 52
TABLE 6 NORTH AMERICA ANTI- INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 53
TABLE 7 NORTH AMERICA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 54
TABLE 8 NORTH AMERICA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 54
TABLE 9 NORTH AMERICA PARTIAL MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 55
TABLE 10 NORTH AMERICA KAPPA AGONIST MU ANTAGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 56
TABLE 11 NORTH AMERICA CORTICOSTEROIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 57
TABLE 12 NORTH AMERICA CORTICOSTEROIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 57
TABLE 13 NORTH AMERICA ALPHA-2 AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 14 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 61
TABLE 15 NORTH AMERICA BRANDED IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 16 NORTH AMERICA GENERIC IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 17 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 64
TABLE 18 NORTH AMERICA PRESCRIPTION BASED IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 19 NORTH AMERICA OTC IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 20 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 21 NORTH AMERICA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 22 NORTH AMERICA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 67
TABLE 23 NORTH AMERICA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 24 NORTH AMERICA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 69
TABLE 25 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 72
TABLE 26 NORTH AMERICA CHRONIC PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 27 NORTH AMERICA ACUTE PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 28 NORTH AMERICA POST OPERATIVE PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 29 NORTH AMERICA DENTAL PAIN IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 30 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 77
TABLE 31 NORTH AMERICA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 32 NORTH AMERICA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 77
TABLE 33 NORTH AMERICA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 34 NORTH AMERICA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 78
TABLE 35 NORTH AMERICA SEMI SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 36 NORTH AMERICA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 79
TABLE 37 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 83
TABLE 38 NORTH AMERICA PARENTERAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 39 NORTH AMERICA ORAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 40 NORTH AMERICA TOPICAL IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 41 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 42 NORTH AMERICA VETERINARY HOSPITALS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 43 NORTH AMERICA VETERINARY CLINICS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 44 NORTH AMERICA PET SHOPS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 45 NORTH AMERICA ANIMAL FARMS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 46 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 47 NORTH AMERICA OTHERS IN VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 48 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 92
TABLE 49 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 92
TABLE 50 NORTH AMERICA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 92
TABLE 51 NORTH AMERICA ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 93
TABLE 52 NORTH AMERICA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 93
TABLE 53 NORTH AMERICA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 54 NORTH AMERICA PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 55 NORTH AMERICA KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 94
TABLE 56 NORTH AMERICA CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 57 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 95
TABLE 58 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 95
TABLE 59 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 60 NORTH AMERICA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 61 NORTH AMERICA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 96
TABLE 62 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 97
TABLE 63 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 97
TABLE 64 NORTH AMERICA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 97
TABLE 65 NORTH AMERICA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 98
TABLE 66 NORTH AMERICA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 98
TABLE 67 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 98
TABLE 68 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 69 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 70 U.S. ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 71 U.S. ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 72 U.S. OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 73 U.S. MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 74 U.S. PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 75 U.S. KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 76 U.S. CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 77 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 78 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 103
TABLE 79 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 80 U.S. COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 81 U.S. PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 82 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 104
TABLE 83 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 104
TABLE 84 U.S. SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 105
TABLE 85 U.S. LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 105
TABLE 86 U.S. SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 105
TABLE 87 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 106
TABLE 88 U.S. VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 89 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 90 CANADA ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 91 CANADA ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 92 CANADA OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 93 CANADA MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 94 CANADA PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 95 CANADA KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 96 CANADA CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 97 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 98 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 110
TABLE 99 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 100 CANADA COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 101 CANADA PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 102 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 112
TABLE 103 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 112
TABLE 104 CANADA SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 112
TABLE 105 CANADA LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 113
TABLE 106 CANADA SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 113
TABLE 107 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 113
TABLE 108 CANADA VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 109 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 110 MEXICO ANALGESICS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 111 MEXICO ANTI-INFLAMMATORY (NSAIDS) IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 112 MEXICO OPIOIDS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 113 MEXICO MU AGONISTS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 114 MEXICO PARTIAL MU AGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 115 MEXICO KAPPA AGONIST-MU ANTAGONIST IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 116 MEXICO CORTECOSTERIODS IN VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 117 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 118 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE, 2021-2030 (USD THOUSAND) 118
TABLE 119 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 120 MEXICO COMPANION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 121 MEXICO PRODUCTION ANIMAL IN VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 122 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE, 2021-2030 (USD THOUSAND) 119
TABLE 123 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 120
TABLE 124 MEXICO SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 120
TABLE 125 MEXICO LIQUID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 120
TABLE 126 MEXICO SEMI-SOLID IN VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE, 2021-2030 (USD THOUSAND) 121
TABLE 127 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 128 MEXICO VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121

LIST OF FIGURES

FIGURE 1 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: MARKET END USER COVERAGE GRID 30
FIGURE 8 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: DBMR MARKET POSITION GRID 32
FIGURE 9 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: VENDOR SHARE ANALYSIS 33
FIGURE 10 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: SEGMENTATION 37
FIGURE 11 INCREASING PET OWNERSHIP AND ADVANCEMENTS IN VETERINARY MEDICINE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET FROM 2023 TO 2030 38
FIGURE 12 THE ANALGESICS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET IN 2023 & 2030 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET 43
FIGURE 14 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY PRODUCT TYPE, 2022 51
FIGURE 15 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY DRUG TYPE, 2022 60
FIGURE 16 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY MODE OF PURCHASE, 2022 63
FIGURE 17 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY ANIMAL TYPE, 2022 66
FIGURE 18 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY PAIN SOURCE, 2022 71
FIGURE 19 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY DOSAGE, 2022 76
FIGURE 20 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 82
FIGURE 21 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: BY END USER, 2022 86
FIGURE 22 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 122